Skip to content

Biohaven BHVN Common stock, shares authorized (in shares)

Common stock, shares authorized (in shares) at other companies

Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
Roivant Sciences logo
Roivant SciencesROIV
BridgeBio Pharma logo
BridgeBio PharmaBBIO
ADMA Biologics logo
ADMA BiologicsADMA
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's common stock, shares authorized (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's common stock, shares authorized (in shares)?
Biohaven (BHVN) reported common stock, shares authorized (in shares) of $200M in Q1 2026.
How has Biohaven's common stock, shares authorized (in shares) changed year-over-year?
Biohaven's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $200M to $200M.
What is the long-term trend for Biohaven's common stock, shares authorized (in shares)?
Over 3 years (2022 to 2025), Biohaven's common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $200M to $200M.